Cell Therapy for Immunomodulation in Kidney Transplantation

  • End date
    Apr 26, 2023
  • participants needed
  • sponsor
    Thomas Wekerle
Updated on 26 January 2021
immunosuppressive agents
kidney transplant
blood type


This study investigates treatment with recipient regulatory T cells and donor bone marrow together with tocilizumab for immunomodulation in living donor kidney transplant recipients.

Condition Organ Transplantation, Renal transplant, Organ Transplant - Pediatric, Organ Transplant, Kidney Transplantation, kidney transplant, renal transplantation, kidney transplants
Treatment Tocilizumab, Kidney Transplant, Regulatory T cells, Regulatory T cells, Bone marrow, Bone marrow, Immunosuppressive drug therapy
Clinical Study IdentifierNCT03867617
SponsorThomas Wekerle
Last Modified on26 January 2021


Yes No Not Sure

Inclusion Criteria

Patient has provided written informed consent
Patient is 18 years or older
Patient is a planned recipient of a living donor kidney transplant
Patient is a planned recipient of an ABO blood group-compatible kidney graft
Patient is a planned recipient of a kidney graft from a donor that is not HLA (human leukocyte antigen)-identical
Patient is negative for DSA (donor-specific antibodies)
WOCBP (women of child-bearing potential) must have a negative pregnancy test at inclusion
WOCBP must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 12 weeks after the study in such a manner that the risk of pregnancy is minimized

Exclusion Criteria

Patient is EBV (epstein barr virus)-negative on serology
Patient is HIV-positive or suffering from chronic viral hepatitis
Patient is CMV (cytomegalo virus)-negative and receiving a kidney from a CMV-positive donor
Positive T-cell lymphocytotoxic cross match
Patient with prior kidney transplant or non-renal solid organ transplant
Patient has a known contraindication to any of the protocol-specified treatments
Patient had been diagnosed with a malignancy within 5 years prior to study entry, excluding non-metastatic basal or squamous cell carcinoma of the skin
Female patients who are breast-feeding
Female patients with a positive pregnancy test
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note